fr   en
Agreements
Select a partner :
Type of agreement :





Select a compound/Disease :
Choose date:
[<<]      «      11   |   12   |   13   |   14   |   15   |   16   |   17   |   18   |   19   |   20   |   21      »      [65]
Date Partners Compound / Disease area / Development phase Type of agreement Nature / Financial terms
2009-11-25 Incyte Corporation (USA)
Novartis (Switzerland)
- The lead compound is a Janus kinase (JAK) inhibitor with the investigational name INCB18424.

- The second compound is a mesenchymal-epithelial transition factor kinase (cMET) inhibitor with the investigational name INCB28060.

/ myelofibrosis
hematological cancers
licensing
commercialization/ distribution
development
See details
2009-11-24 Clavis Pharma (Norway)
Clovis Oncology (USA)
CP-4126 (patented, lipid-conjugated form of the anti-cancer drug gemcitabine)
It was generated using Clavis Pharma's proprietary Lipid Vector Technology and has been designed to improve the therapeutic profile of gemcitabine (Gemzar®) so that it can enter cancer cells without requiring uptake by a specific transporter molecule.

CP-4126 has been granted orphan drug status for the treatment of pancreatic cancer in the European Union and is currently being considered for a similar designation by the FDA in the US.
/ pancreatic cancer and certain other solid tumours
commercialization/ distribution
development
See details
2009-11-19 ARTES Biotechnology (Germany)
Minapharm (Egypt)
undisclosed therapeutic protein R&D
manufacturing
other
See details
2009-11-19 Innate Pharma (France)
Celgene (USA)
combination treatment of lenalidomide (Revlimid®) plus IPH 2101 (fully human anti-KIR monoclonal antibody)

Lenalidomide also activates NK cells (Hayashi et al. 2005, Reddy et al. 2007). Since IPH 2101 potentiates NK cells’ anti-tumor activity, it is expected that lenalidomide and IPH 2101 should have a synergistic effect. This synergy has been documented in vitro on multiple myeloma cell lines. / multiple myeloma
development
other
See details
2009-11-17 bioMérieux (France)
GSK (UK)
companion diagnostic / breast cancer R&D
commercialization/ distribution
See details
2009-11-16 Inostics (subsidiary of Indivumed - Germany)
Johns Hopkins University (USA)
Detection of PIK3CA mutations
/ cancer
licensing
See details
2009-11-16 Nabi Biopharmaceuticals (USA)
GSK (UK)
nicotine conjugate candidate vaccine NicVAX®

The vaccine stimulates the immune system to produce antibodies that bind to nicotine creating an antigen/antibody complex that is too large to cross the blood-brain barrier. In this way, it blocks nicotine from reaching nicotine receptors in the brain and prevents the addictive pleasure sensation experienced by smokers and users of nicotine products. Pre-clinical and previous clinical data show that NicVAX®'s ability to block nicotine from reaching the brain could help people quit smoking. / nicotine addiction and prevention of smoking relapse
licensing
commercialization/ distribution
development
marketing/ promotion
See details
2009-11-13 BioInvent International (Sweden)
Daiichi Sankyo (Japan)
therapeutic antibodies
This agreement is based on BioInvent's proprietary n-CoDeR® library that contains more than 20 billion of highly diverse, fully human antibody fragments.


R&D
licensing
marketing/ promotion
See details
2009-11-12 PanGenetics (The Netherlands)
Abbott (USA)
PG110 (humanized antibody to Nerve Growth Factor- NGF) / chronic pain
licensing
commercialization/ distribution
marketing/ promotion
See details
2009-11-12 Astex Therapeutics (UK)
GSK (UK)
new candidate drugs against multiple GSK targets
/ undisclosed
R&D
See details
2009-11-11 Isofol Medical (Sweden)
Merck Eprova AG (Switzerland - wholly owned subsidiary of Merck KGaA (Germany)
Modufolin® ([6R]-5,10-methylenetetrahydrofolate)
The product has been originally designed to replace leucovorin as the preferred folate to enhance the activity and reduce associated toxicity of 5-FU (5-fluorouracil). / cancer
licensing
See details
2009-11-10 Regeneron Pharmaceuticals (USA)
Sanofi-Aventis (France)
therapeutic antibodies R&D
licensing
commercialization/ distribution
development
marketing/ promotion
See details
2009-11-09 Endotis Pharma (France)
Catalent Pharma Solutions (USA)
  R&D
development
other
See details
2009-11-09 Covagen (Switzerland)
Philogen (Italy)
isolation of binding proteins against EDB (extra domain B of fibronectin)
EDB is a marker of angiogenesis and has been shown to be useful for the targeted delivery of photosensitizers to neovascular structures in ocular pathological conditions.
R&D
other
See details
2009-11-05 Aureus Pharma (France)
Sanofi-Aventis (France)
knowledge database R&D
other
See details
[<<]      «      11   |   12   |   13   |   14   |   15   |   16   |   17   |   18   |   19   |   20   |   21      »      [65]